Aliases & Classifications for Worth's Syndrome

MalaCards integrated aliases for Worth's Syndrome:

Name: Worth's Syndrome 12 14
Worth Disease 29 69
Benign Form of Worth Hyperostosis Corticalis Generalisata with Torus Platinus 12
Autosomal Dominant Endosteal Hyperostosis 12
Autosomal Dominant Osteosclerosis 12
Worth Syndrome 12


External Ids:

Disease Ontology 12 DOID:0080037

Summaries for Worth's Syndrome

Disease Ontology : 12 A hyperostosis that has material basis in a mutation in the LRP5 gene which results_in increased bone density and bony structures located in palate.

MalaCards based summary : Worth's Syndrome, also known as worth disease, is related to hyperostosis, endosteal and hyperostosis. An important gene associated with Worth's Syndrome is LRP5 (LDL Receptor Related Protein 5), and among its related pathways/superpathways are Development ERBB-family signaling and ErbB signaling pathway. The drugs Abacavir and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and eye.

Related Diseases for Worth's Syndrome

Graphical network of the top 20 diseases related to Worth's Syndrome:

Diseases related to Worth's Syndrome

Symptoms & Phenotypes for Worth's Syndrome

Drugs & Therapeutics for Worth's Syndrome

Drugs for Worth's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2 136470-78-5 65140 441300
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2 154598-52-4 64139
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Protein C Approved Phase 4
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
16 Bone Density Conservation Agents Phase 4,Phase 3
17 Ergocalciferols Phase 4
18 Micronutrients Phase 4,Phase 3
19 Trace Elements Phase 4,Phase 3
20 Vitamins Phase 4,Phase 3
21 Anti-HIV Agents Phase 4,Phase 3,Phase 2
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
25 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
27 Cytochrome P-450 CYP3A Inducers Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
29 Dideoxynucleosides Phase 4,Phase 3
30 Lamivudine, zidovudine drug combination Phase 4,Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2
33 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
34 Protective Agents Phase 4,Phase 3,Phase 2
35 Viscosupplements Phase 4
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Anxiety Agents Phase 4,Phase 3
38 Anticonvulsants Phase 4,Phase 3
39 Antimanic Agents Phase 4
40 Antiparkinson Agents Phase 4,Phase 3
41 calcium channel blockers Phase 4,Phase 3
42 Calcium, Dietary Phase 4,Phase 3,Phase 1
43 Central Nervous System Depressants Phase 4,Phase 3
44 Excitatory Amino Acid Antagonists Phase 4,Phase 3
45 Excitatory Amino Acids Phase 4,Phase 3
46 GABA Agents Phase 4
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
49 Psychotropic Drugs Phase 4,Phase 3
50 Tranquilizing Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 177)

id Name Status NCT ID Phase Drugs
1 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
2 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
3 Intraoperative Floppy Iris Syndrome Completed NCT00711347 Phase 4
4 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
5 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
6 The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis Completed NCT00045760 Phase 4 Drotrecogin alfa (activated)
7 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
8 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
9 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
10 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
11 Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension Completed NCT01126203 Phase 3
12 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3 Terlipressin;Placebo
13 Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002) Completed NCT01553747 Phase 3 JNJ-27018966
14 Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) Completed NCT01100684 Phase 3 Asimadoline;Placebo
15 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Completed NCT00938717 Phase 3 Linaclotide or Matching Placebo
16 An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Completed NCT00730171 Phase 3 Linaclotide
17 Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome Completed NCT00968708 Phase 3 Alogliptin;Placebo
18 Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study Completed NCT01543178 Phase 3 open-label rifaximin;double-blind placebo;double-blind rifaximin
19 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome Completed NCT00658515 Phase 3 Dalcetrapib (RO4607381);Evidence-based medical care for Acute Coronary Syndrome;Placebo
20 Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) Completed NCT00731679 Phase 3 Rifaximin;Placebo
21 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate tablets (250 mg);Placebo tablets
22 Clobazam in Patients With Lennox-Gastaut Syndrome Completed NCT00518713 Phase 3 Clobazam Low Dose;Clobazam Medium Dose;Clobazam High Dose;Placebo
23 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial Completed NCT01000727 Phase 3 Darapladib 160 mg;Placebo
24 Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Completed NCT00067561 Phase 3 Alosetron
25 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
26 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
27 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
28 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
29 Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy Completed NCT01076764 Phase 3 Otamixaban;Placebo (for Otamixaban);UFH;Placebo (for UFH);Eptifibatide;Placebo (for Eptifibatide)
30 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Completed NCT01737814 Phase 3 Saline;MST-188
31 Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Completed NCT01495702 Phase 3 NNRTI;FTC/TDF;Stribild
32 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, Completed NCT01475838 Phase 3 PI;RTV;FTC/TDF;Stribild
33 Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Completed NCT01440569 Phase 3 COBI;DRV;NRTIs
34 Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment Completed NCT01363011 Phase 3 E/C/F/TDF;COBI;ATV;DRV;NRTI
35 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT01041638 Phase 3 Isotretinoin
36 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil
37 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed NCT00566852 Phase 3 Memantine
38 Expanded Access Program for Maraviroc At Multiple Centers Completed NCT00426660 Phase 3 maraviroc
39 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies Completed NCT00163020 Phase 2, Phase 3 17-alpha-hydroxyprogesterone caproate injectable;Placebo
40 Efficacy & Safety of Resatorvid in Adults With Severe Sepsis Completed NCT00143611 Phase 3 Resatorvid;Resatorvid;Placebo
41 Study of Rebamipide Eye Drops to Treat Dry Eye Completed NCT00201981 Phase 3 Rebamipide
42 Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
43 Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia Completed NCT00803023 Phase 3 Sodium Oxybate;Sodium Oxybate & 6 Tablets;Sodium Oxybate & 8 Tablets;Sodium Oxybate Oral Solution (6 grams)
44 A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia. Completed NCT00423813 Phase 3 placebo;Xyrem®
45 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Completed NCT00371137 Phase 3 Xyrem®;Placebo
46 Safety and Efficacy Study of Pregabalin in Fibromyalgia Completed NCT00151489 Phase 3 pregabalin;placebo
47 Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Completed NCT01225562 Phase 3 Ticagrelor 90 mg;Ticagrelor 60 mg;Ticagrelor Placebo
48 A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Completed NCT02105987 Phase 3 ABC/DTG/3TC FDC;Ongoing cART regimen
49 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Completed NCT01263015 Phase 3 Dolutegravir;Atripla;Abacavir/Lamivudine;Abacavir/Lamivudine Placebo;Dolutegravir placebo;Atripla placebo
50 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada Completed NCT00272779 Phase 3 ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV

Search NIH Clinical Center for Worth's Syndrome

Genetic Tests for Worth's Syndrome

Genetic tests related to Worth's Syndrome:

id Genetic test Affiliating Genes
1 Worth Disease 29

Anatomical Context for Worth's Syndrome

MalaCards organs/tissues related to Worth's Syndrome:

Myeloid, Bone, Eye, Heart, Kidney, Brain, Testes

Publications for Worth's Syndrome

Variations for Worth's Syndrome

ClinVar genetic disease variations for Worth's Syndrome:

id Gene Variation Type Significance SNP ID Assembly Location
1 LRP5 NM_002335.3(LRP5): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121908670 GRCh37 Chromosome 11, 68131252: 68131252
2 LRP5 NM_002335.3(LRP5): c.640G> A (p.Ala214Thr) single nucleotide variant Pathogenic rs121908671 GRCh37 Chromosome 11, 68125269: 68125269
3 LRP5 NM_002335.3(LRP5): c.641C> T (p.Ala214Val) single nucleotide variant Pathogenic rs121908672 GRCh37 Chromosome 11, 68125270: 68125270

Expression for Worth's Syndrome

Search GEO for disease gene expression data for Worth's Syndrome.

Pathways for Worth's Syndrome

Pathways related to Worth's Syndrome according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
Show member pathways
12.07 EGF ERBB2
Show member pathways
11.87 EGF ERBB2
Show member pathways
11.87 EGF ERBB2
Show member pathways
11.84 EGF ERBB2
Show member pathways
11.79 EGF ERBB2 LRP5
6 11.74 EGF LRP5
7 11.73 EGF ERBB2
Show member pathways
11.7 EGF LRP5
Show member pathways
11.66 EGF ERBB2
Show member pathways
11.62 EGF ERBB2
11 11.59 EGF ERBB2
Show member pathways
11.52 EGF ERBB2
Show member pathways
11.36 EGF ERBB2
14 11.15 EGF ERBB2
Show member pathways
11.06 EGF ERBB2
16 10.82 EGF ERBB2
17 10.11 EGF ERBB2

GO Terms for Worth's Syndrome

Cellular components related to Worth's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.8 EGF ERBB2 LRP5

Biological processes related to Worth's Syndrome according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.51 EGF ERBB2
2 peptidyl-tyrosine phosphorylation GO:0018108 9.49 EGF ERBB2
3 phosphatidylinositol-mediated signaling GO:0048015 9.48 EGF ERBB2
4 phosphatidylinositol phosphorylation GO:0046854 9.46 EGF ERBB2
5 canonical Wnt signaling pathway GO:0060070 9.43 EGF LRP5
6 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.4 EGF ERBB2
7 positive regulation of MAP kinase activity GO:0043406 9.37 EGF ERBB2
8 ERBB2 signaling pathway GO:0038128 9.32 EGF ERBB2
9 regulation of cell motility GO:2000145 9.26 EGF ERBB2
10 positive regulation of mitotic nuclear division GO:0045840 9.16 EGF LRP5
11 negative regulation of ERBB signaling pathway GO:1901185 8.96 EGF ERBB2
12 Wnt signaling pathway involved in dorsal/ventral axis specification GO:0044332 8.62 EGF LRP5

Molecular functions related to Worth's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.32 EGF ERBB2
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 EGF ERBB2
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.16 EGF ERBB2
4 Wnt-protein binding GO:0017147 8.96 EGF LRP5
5 Wnt-activated receptor activity GO:0042813 8.62 EGF LRP5

Sources for Worth's Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....